The identification of antigenic peptides presented on the tumor cell surface by HLA class I molecules and recognized by tumor-specific cytotoxic T lymphocytes may lead to a peptide vaccine capable of inducing protective cellular immunity. We demonstrate that both HLA-A2-restricted breast and ovarian tumor-specific cytotoxic T lymphocytes recognize shared (3) and MART (melanoma antigen recognized by T cells) (4) in melanoma. The discovery of these genes and peptides substantiates the existence of such antigen systems, but unfortunately, melanoma accounts for only 3% of all malignancies and 1% of all cancer deaths (5).
Cytotoxic T lymphocytes (CTLs) are potent cellular effectors of the immune system. These T cells possess memory and, therefore, can respond to rechallenges by the same antigenic assailant. This arm of the immune system, if induced by a tumor vaccine, could be effective in providing long-term protective immunity. CTLs recognize short peptide sequences presented by the HLA class I molecules on the tumor cell surface (1) . Thus far, human tumor-associated antigens (TAA) that could potentially be useful for a vaccine have been demonstrated only indirectly, with the exception of the MAGE (melanoma antigen) system (2) and, most recently, Pmel 17 (3) and MART (melanoma antigen recognized by T cells) (4) in melanoma. The discovery of these genes and peptides substantiates the existence of such antigen systems, but unfortunately, melanoma accounts for only 3% of all malignancies and 1% of all cancer deaths (5) .
HLA-A2 is expressed in approximately 50% of Caucasians (6) and has been demonstrated to play a critical role in antigen presentation of both viral antigens (7) and tumor antigens from a variety of cancers (8) (9) (10) . HER2/neu is a 185-kDa transmembrane glycoprotein with tyrosine kinase activity and extensive homology to the epidermal growth factor receptor (11) . HER2/neu is ubiquitously expressed in many tumors and known to be overexpressed in approximately 30-40% of all ovarian and breast cancers (12) .
We have shown that tumor-specific CTLs can be demonstrated in the tumor-infiltrating lymphocytes (TILs) isolated from ovarian cancers (13) . We have also found that HLA-A2 presents TAA in this disease (14) . The level of expression of the HER2/neu oncogene in ovarian cancer positively correlates with recognition by HLA-A2+ ovarian tumor-specific CTLs, and HLA-A2+ melanoma cells transfected with the HER2/neu gene become sensitive to ovarian cancer-specific CTLs (15) . Therefore, HLA-A2-presented, HER2/neuderived antigenic peptides may be recognized by ovarian cancer-specific CTLs and, potentially, by breast cancerspecific CTLs as well.
In this study, we have searched the HER2/neu sequence (16) for HLA-A2-binding peptides (17) , and we have found that both ovarian and breast cancer-specific CTLs recognize a nine-amino acid peptide from the transmembrane portion of the HER2/neu protein (GP2; amino acids 654-662). This peptide is widely expressed in HER2/neu+ tumors and is capable of inducing HLA-A2-restricted, tumor-specific CTL populations in vitro.
METHODS
Generation of Tumor-Specific CTLs. Tumor-specific CTLs were generated from fresh tumor specimens obtained through the Departments of Surgery, Gynecologic Oncology, and Pathology at Brigham and Women's Hospital (BWH) and Beth Israel Hospital in Boston, under approval of the Institutional Review Boards. Solid tumor specimens were processed as previously described (14) . Briefly, specimens were minced manually and enzymatically digested, and the lymphocytes and tumor cells were separated by centrifugation over discontinuous Ficoll (Organon Teknika-Cappel) gradients. TILs were suspended in RPMI-1640 medium (BioWhittaker) supplemented with 10% fetal calf serum (BioWhittaker) and antibiotics. Cultures were suspended at 5 x 105 cells per ml on solid-phase, anti-CD3 polystyrene plates (Orthoclone OKT3, Ortho Pharmaceuticals) for 48 h. T cells were then maintained in culture with 50 international units per ml of interleukin 2 (IL-2) (Amgen Biologicals). At 1, 3, and 5 wk, autologous, irradiated (10,000 rad from cesium source; 1 rad = 0.01 Gy) tumor cells were added to the T-cell cultures at a 10:1 lymphocyte-to-tumor cell ratio.
Phenotype Analysis. The HLA-A2 status of the tumor cells was determined by indirectly staining 10 ,lI of a 1:10 dilution of culture suspension with anti-HLA-A2 monoclonal antibodies (mAbs) BB activation. The control cultures were maintained in a low concentration of interleukin 2 (50 international units per ml) and expanded as required. The peptide-educated cultures were stimulated with irradiated T2 cells pulsed with the GP2 peptide weekly for 3 wk. These cultures were then tested for their ability to recognize T2, GP1-pulsed T2, GP2-pulsed T2, and HLA-A2+ and HLA-A2-allogeneic tumor targets in standard cytotoxicity assays.
PCR Amplification and cDNA Sequencing. Approximately 2-5 x 106 tumor cells from ovarian cancers were lysed and total cellular RNA was isolated by ultracentrifugation in guanidinium isothiocyanate/cesium chloride. First strand cDNA was generated from 1 ,ug of total RNA by using oligo(dT) and reverse transcriptase in a reaction volume of 20
Al. PCR was performed using a mixture of reaction buffer (Perkin-Elmer/Cetus), deoxynucleotides, Taq DNA polymerase (Perkin-Elmer/Cetus), cDNA, and primers in a final reaction volume of 25 ,ul. Primers were constructed to amplify approximately 200 bp containing the transmembrane portion of the HER2/neu protein (forward primer was 5'-CAT-CAACTGCACCCACTCCT and reverse primer was 5'-GCAGCAGTCTCCGCATCGTG). One cycle of PCR consisted of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and elongation at 72°C for 2 min. A total of 30 cycles were performed, and the last cycle was followed by a 7-min extension at 72°C. For sequencing, 15 Al of the primary PCR reaction mixture was resolved on a 1.5% low-melting-point agarose gel, and appropriately amplified PCR products were isolated using the Quiax gel extraction kit (Quiagen, Chatsworth, CA). Sequencing was performed by using a modification of the dideoxy chain termination method with Sequenase Version 2.0 (United States Biochemical). Samples were loaded onto a 6% polyacrylamide denaturing gel containing 7 M urea. Dried gels were autoradiographed using X-Omat AR film (Eastman Kodak).
RESULTS

HLA-A2-Restricted Crossreactivity of Breast and Ovarian
Tumor-Specific CTLs. To determine if a common antigen system exists between ovarian and breast cancers, we isolated TILs from a series of HLA-A2+, HER2/neu+ ovarian (OvTIL) and breast (BrTIL) cancer specimens. The TILs were cultured with repeated stimulation by autologous tumor cells until the cultures revealed tumor-specific cytotoxicity as previously described (13) . As shown in Fig. 1A , the HLA-A2+ OvTIL1, OvTIL2, and OvTIL3 lines recognized the HLA-A2+ ovarian tumor lines significantly better (P < 0.05) than the HLA-A2-lines, confirming our previous report (14) . Likewise, the HLA-A2+ BrTIL1, BrTIL2, and BrTIL3 lines significantly (P < 0.05) recognized only HLA-A2+ breast cancer lines (Fig. 1B) . More importantly, the OvTILs recognized the breast cancer lines in a HLA-A2-restricted manner, and the BrTILs recognized the ovarian cancers similarly (Fig. 1 C and D, respectively, P < 0.05). Neither the OvTILs nor the BrTILs recognized HLA-A2+ melanomas, nor did either HLA-A2-OvTILs or BrTILs lyse the HLA-A2+ cancer lines (data not shown). The HER2/neu expression in the HLA-A2+ and HLA-A2-tumors was comparable (data not shown). These data suggest that HLA-A2 serves as a restriction element in breast cancer also, but more importantly, at least one common tumor antigen system that is presented by the HLA-A2 allele exists between these closely related malignancies.
Acid Elution of Endogenously Expressed, Commonly Recognized TAA. The existence of antigenic peptides presented on the tumor cell surface by HLA class I can be directly demonstrated. We have loaded acid-eluted (19) and HPLCfractionated peptides on the T2 cell line and found that multiple peptides exist that induced recognition by ovarian tumor-specific CTLs (Fig. 2A) . Several of the peptide fractions acid-eluted from ovarian tumor cells were also recognized by BrTILs (Fig. 2B) , thus confirming by another method the existence of shared TAA between these two cancers. HER2/neu-Derived Synthetic Peptides. As previously stated, the HER2/neu sequence was searched for HLA-A2-binding peptides, and in the transmembrane portion of the protein there is a peptide with the same HLA-A2-binding dominant residues (17) as found in the immunogenic influenza matrix peptide 58-66 (XIXXXVXXL) (20) . Therefore, we synthesized the peptide (654-662) with the sequence IISAV-VGIL (GP2), to test if this peptide constitutes a T-cell epitope. We also constructed a control peptide from the sequence (650-658) PLTSIISAV (GP1), which has a known binding affinity for HLA-A2 (21) . The T2 cell line (18) was loaded with the synthetic peptides, and four HLA-A2+ ovarian cancerspecific TIL lines recognized the GP2 peptide but not the GP1 peptide or the unloaded T2 (P < 0.05) (Fig. 3A) . The level of killing ranged from 10 to 20% but was generally lower than the cytotoxicity against an allogeneic tumor control. Of extreme interest, three HLA-A2+ breast cancer-specific TIL lines also recognized the GP2 peptide but not the GP1 peptide or unloaded T2 (P < 0.05) (Fig. 3B) . The BrTIL (P < 0.05) (data not shown). The level of BB 7.2 blocking was equal to that of the anti-HLA-A,B,C mAb W6/32, demonstrating that HLA-A2 is the only class I molecule presenting this peptide to these CTLs, as expected. These findings suggest that both ovarian cancer-specific and breast cancer-specific CTLs recognize a HER2/neu-derived peptide presented by HLA-A2.
In Vitro Sensitization of TIL with GP2. Fresh TILs that were sensitized to GP2 through repeated stimulations with GP2-pulsed T2 demonstrated an enhanced ability to recognize the GP2 peptide as compared with GP1-pulsed T2 or unloaded T2 (P < 0.05) (Fig. 4) . In addition, the GP2-sensitized TILs were able to recognize HLA-A2+, HER2/neu+ allogeneic tumors 2-to 3-fold better than unsensitized control TILs (P < 0.05) (D.C.L., G.E.P., D. T. Hess, I. C. Summerhayes, A. S. Parikh, P. S. Goedegebuure, and T.J.E, unpublished data). Further- more, this tumor recognition was specific and HLA-A2-restricted (Fig. 4) with significantly greater recognition of HLA-A2+ tumor cells as compared with HLA-A2-tumor targets (P < 0.05).
Endogenous Expression of GP2 in Ovarian Cancer. According to one report, there is a valine instead of an isoleucine at position 655 (11) ; therefore, to confirm in ovarian cancer the expression of the peptide 654-662 as previously described in breast (22, 23) and gastric (16) cancers, we constructed PCR primers predicted to amplify the transmembrane domain of the HER2/neu mRNA. The amplified cDNA was directly sequenced, and in three consecutive ovarian tumors, isoleucine was found at position 655. These data confirm the expression of the GP2 peptide in ovarian cancer.
DISCUSSION
Finding a specific peptide derived from the HER2/neu sequence that is recognized by tumor-specific CTLs confirms that this oncogene serves as a tumor antigen system. HER2/ neu is widely expressed in many different tumors, and the GP2 peptide has been sequenced from breast (22, 23) and gastric (16) cancers, and now from ovarian cancers as well. The isoleucine at position 655 is likely to be the most common amino acid residue; however, a neutral substitution of valine at position 655 has been described in the HER2/neu expressed in normal tissue by Coussens et at (11) . Since a valine at position 2 of the GP2 peptide would drastically decrease its affinity for HLA-A2 (17) , the GP2 peptide would be theoretically a tumor-specific target. Unfortunately, due to the extremely low level of HER2/neu expression in normal tissue, we have not been able to confirm the sequence in normal tissue. However, even if this peptide is not tumor-specific, the difference in levels of HER2/neu expression between normal tissue and tumors would still allow this peptide to be utilized therapeutically.
The elution experiments demonstrate that there are other peptides that induce a CTL response. The HPLC fractions may contain antigenic peptides from mutated proteins, exclusively expressed tumor proteins, or other overexpressed normal proteins like HER2/neu that may be amplified as much as 20-fold in ovarian and breast cancers (12) . The HER2/neu gene has been shown to transform NIH 3T3 cells (23) ; therefore, the immune system may recognize this potentially harmful protein when it is overexpressed. Recent reports suggest that normal HER2/neu-derived peptides may be recognized by CD4+ T cells (24) and ovarian tumor-specific CTLs (25) . However, in the latter study, the 14-amino acid peptides recognized by a single CTL line would not be predicted to bind HLA-A2 as suggested (17, 21) . Normal proteins have been documented, however, to be recognized by the immune system in melanoma (26) . In fact, all of the melanoma TAA described thus far are also expressed in normal tissue (2) (3) (4) (Fig. 4) . The synthetic peptide can be mass produced and theoretically exploited for stimulating therapeutic tumor-specific CTLs for any HER2/neu+ malignancy expressing the peptide. This list currently includes breast, ovarian, and gastric cancers, and non-small-cell lung cancer will probably soon be added. Additional cancers to be tested include pancreatic and colon cancers. The level of expression of the GP2 peptide in these tumors will obviously impact the effectiveness of any therapeutic modalities targeting the peptide; however, highly sensitive and specific CTL cultures can be generated. The current limitations of the GP2 peptide, apparent in the level of cytotoxicity demonstrated in Fig. 3 
